ROCHE HOLDINGS AG (RHHBY)

33.76
0.36 1.06
OTC
Prev Close 34.12
Open 33.80
Day Low/High 33.67 / 33.94
52 Wk Low/High 26.30 / 34.98
Volume 870.52K
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)
Shionogi's Single-Dose Flu Drug Gets Japanese Approval

Shionogi's Single-Dose Flu Drug Gets Japanese Approval

The drug likely wouldn't be approved in the U.S. before 2019, however.

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) as a first-line...

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street futures are edging higher amid a "Super Thursday" of corporate earnings that will culminate with Apple's much-anticipated quarterly update and the first official indication on sales of its flagship iPhone X.

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

Roche And Ignyta Reach Definitive Merger Agreement

Roche And Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan ® (rituximab)...

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated...

Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan (BR) Increased Complete Response Rates Compared To BR Alone In Previously Treated Aggressive Lymphoma

Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan (BR) Increased Complete Response Rates Compared To BR Alone In Previously Treated Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the randomized Phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus...

Genentech's HEMLIBRA (emicizumab-kxwh) Continued To Substantially Reduce Bleeds In People With Hemophilia A With Inhibitors

Genentech's HEMLIBRA (emicizumab-kxwh) Continued To Substantially Reduce Bleeds In People With Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the ongoing HEMLIBRA ® (emicizumab-kxwh) clinical development program were presented at the 59th American Society...

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Chemotherapy Reduced The Risk Of Disease Worsening Or Death By 38 Percent For People With A Type Of Advanced Lung Cancer

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Chemotherapy Reduced The Risk Of Disease Worsening Or Death By 38 Percent For People With A Type Of Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive, pivotal Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus...

Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds In Phase III Study In Hemophilia A

Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds In Phase III Study In Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive interim results from the Phase III HAVEN 4 study evaluating HEMLIBRA ® (emicizumab-kxwh) prophylaxis dosed once every four...

FDA Grants Genentech's Avastin Full Approval For Most Aggressive Form Of Brain Cancer

FDA Grants Genentech's Avastin Full Approval For Most Aggressive Form Of Brain Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche sees success in trials for its cancer and hemophilia drugs

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) And Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) And Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Genentech's HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds In Phase III Study In Hemophilia A

Genentech's HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds In Phase III Study In Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III HAVEN 3 study evaluating HEMLIBRA ® (emicizumab-kxwh) in adults and adolescents (aged 12 years or...

FDA Approves Genentech's Gazyva For Previously Untreated Advanced Follicular Lymphoma

FDA Approves Genentech's Gazyva For Previously Untreated Advanced Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

(Photo: Business Wire)

(Photo: Business Wire)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Approves Genentech's Alecensa (Alectinib) As First-Line Treatment For People With Specific Type Of Lung Cancer

FDA Approves Genentech's Alecensa (Alectinib) As First-Line Treatment For People With Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Zelboraf (Vemurafenib) For Erdheim-Chester Disease With BRAF V600 Mutation

FDA Approves Zelboraf (Vemurafenib) For Erdheim-Chester Disease With BRAF V600 Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech To Present New Data Across A Range Of Blood Diseases At The American Society Of Hematology (ASH) 2017 Annual Meeting

Genentech To Present New Data Across A Range Of Blood Diseases At The American Society Of Hematology (ASH) 2017 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on its approved and investigational medicines for blood diseases will be presented at the 59 th American Society of...

New OCREVUS (Ocrelizumab) Data At ECTRIMS Advance Clinical Understanding Of Underlying Progression In Multiple Sclerosis

New OCREVUS (Ocrelizumab) Data At ECTRIMS Advance Clinical Understanding Of Underlying Progression In Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple...

FDA Accepts Genentech's Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian Cancer

FDA Accepts Genentech's Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS

Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be...